11/3/2026

speaker
Julianne
Conference Facilitator

My name is Julianne and I will be your conference facilitator today for the Amgen Q3 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star then the number one on your telephone keypad. To a third question, please press star one again. I would now like to introduce Casey Capparelli, Vice President of Investor Relations. Mr. Capparelli, you may now begin.

speaker
Casey Capparelli
Vice President, Investor Relations

Thank you, Julianne. Good afternoon, everyone, and welcome to our third quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner, and Thomas Dietrich. Through the course of our discussion today, We will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our Safe Harbor Statement. And please note that actual results can vary materially. Over to you, Bob.

speaker
Robert A. Bradway
Chairman and Chief Executive Officer

Good afternoon, and thank you for joining our call. Our results through the first three quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules. This is exactly the kind of performance our strategy was designed to achieve. Strong commercial and operations execution and continued innovation from our research and development organization reinforce our confidence in Amgen's ability to deliver durable long-term growth. For the latest quarter, total revenues grew a strong 8% year-over-year to $10.4 billion. Our six key growth drivers grew 27% year over year and represented over 70% of our third quarter product sales. Across the portfolio, 17 products delivered double digit sales growth and 17 products are now annualizing at more than $1 billion based on third quarter sales. We see significant opportunity to build on this momentum. Many of our medicines address large, under-penetrated disease areas where the majority of patients remain untreated. Repatha, Avenity, and Tespire are clear examples of that. Our strong financial performance gives us the flexibility to invest in innovation and the capabilities needed to support future growth while delivering attractive returns to shareholders. In the third quarter, We generated $3.7 billion in free cash flow, increased our investment in research and development by 11% year-over-year, and invested another $600 million in the business through capital expenditures. This was another productive quarter for our R&D organization. We reported positive Phase III results from three important programs. Imdeltra in small cell lung cancer, where we are working to establish it as the cornerstone therapy, Tez Spire in eosinophilic esophagitis, an area with significant unmet need, and Dezodalibep in Sjogren's disease, where no approved disease-modifying therapies currently exist. I would note that each of these represents an established or potential first-in-class medicine with the opportunity to make a meaningful difference for patients while providing additional sources of long-term growth for Amgen. Likewise, our progress reflects the strength of our science and our commitment to pursuing novel approaches for serious diseases. That same focus guides our investment in programs such as Maritide, which is advancing through Phase III development. Jay will discuss these programs and our other clinical advances in more detail shortly. We're also leveraging technology, data-driven insights, and artificial intelligence across Amgen to improve the speed and efficiency of how we discover, develop, manufacture, and deliver medicine to patients. We're encouraged by our performance this quarter and our broad portfolio Continued investment in advancing pipeline give us confidence in Amgen's ability to deliver durable growth well into the next decade. I want to thank our colleagues around the world for their dedication to our mission to serve patients and for the quality of their work every day. With that, we'll turn it over to Murdo.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation